Citigroup Downgrades Bio-Techne to Neutral, Raises Price Target to $73

Benzinga Newsdesk www.benzinga.com Negative 85.7%

Neg 85.7% Neu 0% Pos 0%

Citigroup analyst Patrick Donnelly downgrades Bio-Techne (NASDAQ:TECH) from Buy to Neutral and raises the price target from $70 to $73.